IP Library Granted Patent US 7,642,260
Granted Patent B2
US 7,642,260 · App. 11/202,827 · Granted Jan 5, 2010

Apoptosis promoters

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,642,260
App. No.
11/202,827
Granted
Jan 5, 2010
Kind
B2
Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member.

Claims (2)

1. A method of treating brain cancer, breast cancer, bone marrow cancer, chronic lymphocytic leukemia, colorectal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide.

2. A method of treating brain cancer, breast cancer, bone marrow cancer, chronic lymphocytic leukemia, colorectal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030182/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2006
From: BRUNCKO, MILAN; DING, HONG; ELMORE, STEVEN W.; KUNZER, AARON R.; LYNCH, CHRISTOPHER L.; MCCLELLAN, WILLIAM J.; PARK, CHEOL-MIN; PETROS, ANDREW M.; SONG, XIAOHONG; WANG, XILU; TU, NOAH P.; WENDT, MICHAEL D.; SHOEMAKER, ALEXANDER R.; MITTEN, MICHAEL J.
To: ABBOTT LABORATORIES
Reel/Frame 017413/0198 →